Alzheimer’s disease is responsible for up to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts with difficulty remembering recent events. It is often a patient’s family member that notices this loss of function and that urges the patient to see the doctor. Presently, there…
In a recent study published in the journal Computational and Mathematical Methods in Medicine, a team of researchers found that the use of multiscale entropy analysis (MSE), of EEG signals, especially Slope 2, provides a potential tool for predicting the efficacy of AChE inhibitors prior to…
A recent study titled, “ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment,” reported in this month’s issue of The FASEB Journal, is backing all the hype surrounding fish oil and antioxidant supplements as a potential means to…
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company addressing the cognitive, behavioral, and functional components of dementia, recently announced that two presentations on the company’s drug development efforts have been accepted for the 2015 International Conference of the Alzheimer’s Association (AAIC) that will take place in Washington, D.C. from the…
In a recent study published in the Journal of Neuroinflammation, researchers from China were able to identify a new target to address the Neuroinflammation found in patients with Alzheimer’s disease. Neuroinflammation, characterized by excessive glial activation and overproduction of proinflammatory cytokine and chemokines, plays a critical…
Type 2 diabetes is a condition that normally occurs in late adulthood, and patients with the disease are at increased risk for dementia when compared to non-diabetics. In a recent study, Michael…
UK-based Dementia Consortium announced that it will grant £500,000 ($790,000) in funding to a collaborative research effort that includes academics from the University of Southampton and drug discovery specialists from the medical research charity MRC Technology. The newly-funded project will focus on targeting the immune system in order to develop new therapeutic options to treat Alzheimer’s disease.
Actinogen Limited, a biotechnology company focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia, recently announced that it has received approval for the third and final stage of the second…
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Stemedica Cell Technologies, Inc. The approval means that the company is allowed to initiate a phase 2a clinical study to evaluate the use of an allogeneic stem-cell therapy for…
Phoenix-based Banner Alzheimer’s Institute (BAI) was recently awarded a joint $10 million research funding grant from the Alzheimer’s Association, GHR Foundation and Fidelity Biosciences Research Initiative. The three organizations announced their plan to fund BAI’s efforts, given the organization’s reputation as an internationally recognized Alzheimer’s care and…
Get regular updates to your inbox.